Abstract:

Objective　To investigate the clinical effect of Shugan Hezhong Jiangni prescription in the treatment of patients with reflux esophagitis and Zhongxu Qini syndrome. Methods　A total of 62 patients with reflux esophagitis treated in Ningxia Chinese Medicine Research Center from July 2020 to January 2022 were selected for the randomized controlled trial, and were divided into an observation group and a control group by the random number table method, with 31 cases in each group. There were 20 males and 11 females in the control group; they were 34-78 (54.67±10.01) years old; their disease course was 2-11 (5.99±2.01) months. There were 21 males and 10 females in the observation group; they were 35-79 (55.85±10.34) years old; their disease course was 2-12 (6.23±2.11) months. The control group were treated with rabeprazole sodium enteric-coated capsules and mosapride, and the observation group with Shugan Hezhong Jiangni prescription. Both groups were treated for 60 d. The clinical efficacies, gastroscopy grades, and incidences of adverse reactions were compared between the two groups. t and χ² tests were applied. Results　After the treatment, the scores of main symptoms and secondary symptoms and the total score decreased in both groups (P<0.05), and the scores of the observation group were lower than those of the control group [(7.23±1.46) vs. (10.29±1.85), (2.97±1.03) vs. (4.85±1.74), and (10.20±1.65) vs. (15.14±2.37)], with statistical differences (t=8.212, 5.880, and 10.819; all P<0.05). The total effective rate of the observation group was higher than that in the control group [90.32% (28/31) vs. 64.52% (20/31), with a statistical difference (χ²=5.905, P<0.05). After the treatment, fewer patients had grade C and D of Los Angeles Grading (LA) in the observation group than in the control group [22.58% (7/31) vs. 48.39% (15/31)], with a statistical difference (χ²=4.509, P<0.05). During the treatment, the incidence of adverse reactions was 9.68% (3/31) in the observation group, and was 6.45% (2/31) in the control group, with no statistical difference between the two groups (correction χ²=0.218, P>0.05). Conclusion　Shugan Hezhong Jiangni prescription in the treatment of patients with reflux esophagitis and Zhongxu Qini syndrome can relieve their symptoms and is effective, safe, and reliable.

Key words:

Reflux esophagitis, Zhongxu Qini syndrome, Shugan Hezhong Jiangni prescription

摘要：

目的　探讨疏肝和中降逆方治疗反流性食管炎中虚气逆证患者的临床效果。方法　选取2020年7月至2022年1月宁夏回族自治区中医医院暨中医研究院收治的62例反流性食管炎患者进行随机对照试验，依照随机数字表法分为观察组和对照组，各31例。对照组男性20例、女性11例，年龄34～78（54.67±10.01）岁，病程2～11（5.99±2.01）个月，采用雷贝拉唑钠肠溶胶囊联合莫沙比利治疗；观察组男性21例、女性10例，年龄35～79（55.85±10.34）岁，病程2～12（6.23±2.11）个月，给予疏肝和中降逆方治疗。两组治疗时间均为60 d。对比两组患者的临床疗效、胃镜分级以及不良反应发生情况。统计学方法采用t检验、χ²检验。结果　治疗后，两组患者主症、次症、总分均较治疗前降低，观察组主症、次症、总分均低于对照组［（7.23±1.46）分比（10.29±1.85）分、（2.97±1.03）分比（4.85±1.74）分、（10.20±1.65）分比（15.14±2.37）分］，差异均有统计学意义（t=8.212、5.880、10.819，均P<0.05）。观察组的总有效率高于对照组［90.32%（28/31）比64.52%（20/31）］，差异有统计学意义（χ²=5.905，P<0.05）。治疗后，观察组洛杉矶分级（LA）中C、D级低于对照组［22.58%（7/31）比48.39%（15/31）］，差异有统计学意义（χ²=4.509，P<0.05）。治疗期间观察组不良反应发生率为9.68%（3/31），对照组不良反应发生率为6.45%（2/31），两组对比差异无统计学意义（校正χ²=0.218，P>0.05）。结论　疏肝和中降逆方用于治疗反流性食管炎中虚气逆证，能够缓解患者症状，疗效确切，安全可靠。

关键词:

反流性食管炎, 中虚气逆症, 疏肝和中降逆方